Ng GSK Medicine: Fluticasone propionate/salmeterol, fluticasone propionate/salmeterol/norflurane

Rationale: Monitoring was required for the introduction of non-chlorofluorocarbon (CFC) propellants in metered dose inhalers (MDIs) to ensure that there were no unexpected adverse events due to the new products. A postmarketing observational study was conducted to evaluate the introduction of the MDI Seretide Evohaler TM (hydrofluoroalkane-134a inhaler containing salmeterol and fluticasone propionate). Objectives: The aim of the modified prescription event monitoring (PEM) study was to compare event rates during the three months prior to and three months after the introduction of Seretide Evohaler Indication: asthma Study Investigators/Centers: Drug Research Surveillance Unit (DSRU), Southampton, UK